Time to test CLL p53 function

Blood

Volumn 115, Issue 21, 2010, Pages 4154-4155

  Zent, Clive S ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUDARABINE; MICRORNA; PROTEIN MDM2; PROTEIN P53;

ALLELE; CELL CYCLE; CHROMOSOME 11; CHROMOSOME 17; CHRONIC LYMPHATIC LEUKEMIA; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE EXPRESSION; GENE SEQUENCE; GENETIC CODE; GENOTYPE; HUMAN; IONIZING RADIATION; LOSS OF FUNCTION MUTATION; NOTE; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN FUNCTION; RADIATION EXPOSURE; SINGLE NUCLEOTIDE POLYMORPHISM; UPREGULATION;

EID: 77956418455     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-02-268482     Document Type: Note

References (10)

1. Zenz T, Krober A, Scherer K, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood. 2008;112(8):3322-3329.
2. Malcikova J, Smardova J, Rocnova L, et al. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. Blood. 2009;114(26):5307-5314.
3. Asslaber D, Piñón JD, Seyfried I, et al. microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic anemia. Blood. 2010;115(21):4191-4197.
4. He L, He X, Lowe SW, Hannon GJ. microRNAs join the p53 network: another piece in the tumour-suppression puzzle. Nat Rev Cancer. 2007;7(11):819-822. (Pubitemid 350006254)
5. Mraz M, Malinova K, Kotaskova J, et al. miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. Leukemia. 2009;23(6):1159-1163.
6. Dijkstra MK, van Lom K, Tielemans D, et al. 17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation. Leukemia. 2009;23(3):625-627.
7. Zenz T, Habe S, Denzel T, et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood. 2009;114(13):2589-2597.
8. Zenz T, Mohr J, Eldering E, et al. miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood. 2009;113(16):3801-3808.
9. Gryshchenko I, Hofbauer S, Stoecher M, et al. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia. J Clin Oncol. 2008;26(14):2252-2257.
10. Seyfried I, Hofbauer S, Stoecher M, Greil R, Tinhofer I. SNP309 as predictor for sensitivity of CLL cells to the DM2 inhibitor nutlin-3a [letter]. Blood. 2008;112(5):2168.